{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:24:08Z","timestamp":1783016648212,"version":"3.54.6"},"reference-count":121,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016208","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:23:47Z","timestamp":1749032627000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunomodulators and immunosuppressants for myasthenia gravis: a network meta-analysis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Lucia B","family":"Varela","sequence":"additional","affiliation":[{"name":"Universidad Hospital Italiano de Buenos Aires; Ciudad Aut\u00f3noma de Buenos Aires Argentina"},{"name":"Neurology Department; Italian Hospital of Buenos Aires; Ciudad Aut\u00f3noma de Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Meza","sequence":"additional","affiliation":[{"name":"Interdisciplinary Centre for Health Studies CIESAL; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Micaela","family":"Escobar Liquitay","sequence":"additional","affiliation":[{"name":"Universidad Hospital Italiano de Buenos Aires; Ciudad Aut\u00f3noma de Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"D\u00edaz Menai","sequence":"additional","affiliation":[{"name":"Universidad Hospital Italiano de Buenos Aires; Ciudad Aut\u00f3noma de Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Franco","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK D\u00fcsseldorf Subunit; Institute of General Practice, Centre for Health and Society, Medical Faculty, Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Garegnani","sequence":"additional","affiliation":[{"name":"Universidad Hospital Italiano de Buenos Aires; Ciudad Aut\u00f3noma de Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clinical and Experimental Immunology"},{"issue":"5","key":"10.1002\/14651858.CD016208-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cns.13110","article-title":"Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta-analysis","volume":"25","author":"Wang","year":"2019","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1002\/14651858.CD016208-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurology"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet. Neurology"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.28006","article-title":"Incidence and prevalence of myasthenia gravis in the United States: A claims-based analysis","volume":"69","author":"Rodrigues","year":"2024","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Barohn","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD016208-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of juvenile myasthenia gravis","volume":"11","author":"O'Connell","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/sjmms.sjmms_80_22","article-title":"Thymectomy in myasthenia gravis: A narrative review","volume":"10","author":"Aljaafari","year":"2022","journal-title":"Saudi Journal of Medicine & Medical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD016208-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s13760-024-02552-7","article-title":"Recommendations for the management of myasthenia gravis in Belgium","volume":"124","author":"De Bleecker","year":"2024","journal-title":"Acta Neurologica Belgica"},{"issue":"3","key":"10.1002\/14651858.CD016208-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD016208-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"16","key":"10.1002\/14651858.CD016208-BIB0012|cit12","first-page":"175628642312132","article-title":"Guideline for the management of myasthenic syndromes","volume":"26","author":"Wiendl","year":"2023","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"3","key":"10.1002\/14651858.CD016208-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","article-title":"Myasthenia gravis in 2025: five new things and four hopes for the future","volume":"272","author":"Binks","year":"2025","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD016208-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40259-020-00443-w","article-title":"Monoclonal antibody-based therapies for myasthenia gravis","volume":"34","author":"Alabbad","year":"2020","journal-title":"BioDrugs"},{"issue":"12","key":"10.1002\/14651858.CD016208-BIB0015|cit15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013801","article-title":"Immunoglobulin for myasthenia gravis","author":"Alzuabi","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD016208-BIB0016|cit16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002277.pub4","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD016208-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neurol.2024.09.006","article-title":"New treatment strategies in myasthenia gravis","volume":"180","author":"Attarian","year":"2024","journal-title":"Revue Neurologique"},{"issue":"S1","key":"10.1002\/14651858.CD016208-BIB0018|cit18","first-page":"51","article-title":"Myasthenia gravis: immunological mechanisms and immunotherapy","volume":"37","author":"Lewis","year":"1995","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00415-015-7944-8","article-title":"Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study","volume":"263","author":"Chen","year":"2016","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD016208-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13760-023-02367-y","article-title":"Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study","volume":"124","author":"Qiu","year":"2024","journal-title":"Acta Neurologica Belgica"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0960-8966(00)00173-5","article-title":"Therapeutic options in ocular myasthenia gravis","volume":"11","author":"Evoli","year":"2001","journal-title":"Neuromuscular Disorders: NMD"},{"issue":"6","key":"10.1002\/14651858.CD016208-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2147\/NDT.S3309","article-title":"Mycophenolate mofetil for myasthenia gravis: a clear and present controversy","volume":"4","author":"Heatwole","year":"2008","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD016208-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific \u2013 but not total \u2013 IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1002\/14651858.CD016208-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: principles, evidence and practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Practical Neurology"},{"issue":"12","key":"10.1002\/14651858.CD016208-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: first approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"issue":"16","key":"10.1002\/14651858.CD016208-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD016208-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14656566.2024.2332610","article-title":"Promising therapies for the treatment of myasthenia gravis","volume":"25","author":"Uysal","year":"2024","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD016208-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent cechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1002\/14651858.CD016208-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Nowak","year":"2020","journal-title":"JAMA Neurology"},{"issue":"6","key":"10.1002\/14651858.CD016208-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","article-title":"FcRn inhibitor therapies in neurologic diseases","volume":"38","author":"Alfaidi","year":"2024","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1002\/14651858.CD016208-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/mus.26919","article-title":"Update on immune-mediated therapies for myasthenia gravis","volume":"62","author":"Habib","year":"2020","journal-title":"Muscle & Nerve"},{"issue":"8","key":"10.1002\/14651858.CD016208-BIB0034|cit34","first-page":"e5","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Bril","year":"2021","journal-title":"Lancet Neurology"},{"issue":"10","key":"10.1002\/14651858.CD016208-BIB0035|cit35","first-page":"e11","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD016208-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"e14793","DOI":"10.1111\/cns.14793","article-title":"Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis","volume":"30","author":"Ruan","year":"2024","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD016208-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD016208-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jocn.2023.11.013","article-title":"Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study","volume":"119","author":"Gomez Mancilla","year":"2024","journal-title":"Journal of Clinical Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD016208-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0041|cit41","first-page":"7","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome: An overview","volume":"76","author":"Murai","year":"2024","journal-title":"Shinkei Kenkyu\u0304 No Shinpo [Brain and Nerve]"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","article-title":"The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis","volume":"38","author":"Ma","year":"2024","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1002\/14651858.CD016208-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Sacc\u00e0","year":"2023","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD016208-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"790834","DOI":"10.3389\/fphar.2021.790834","article-title":"Different monoclonal antibodies in myasthenia gravis: A Bayesian network meta-analysis","volume":"12","author":"Song","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD016208-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3389\/fneur.2020.00981","article-title":"From traditional to targeted immunotherapy in myasthenia gravis: prospects for research","volume":"11","author":"Mantegazza","year":"2020","journal-title":"Frontiers in Neurology"},{"key":"10.1002\/14651858.CD016208-BIB0046|cit46","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD016208-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2020","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"11","key":"10.1002\/14651858.CD016208-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD016208-BIB0049|cit49","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016208-BIB0050|cit50","unstructured":"Reeves BC Deeks JJ Higgins JP Shea B Tugwell P Wells GA Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016208-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"10.1002\/14651858.CD016208-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle & Nerve"},{"issue":"5","key":"10.1002\/14651858.CD016208-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle & Nerve"},{"issue":"18","key":"10.1002\/14651858.CD016208-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: A valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mus.21713","article-title":"History of outcome measures for myasthenia gravis","volume":"42","author":"Burns","year":"2010","journal-title":"Muscle & Nerve"},{"issue":"6","key":"10.1002\/14651858.CD016208-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1002\/14651858.CD016208-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/ene.13836","article-title":"EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis","volume":"26","author":"Barnett","year":"2019","journal-title":"European Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mus.21016","article-title":"Disease-specific measure of quality of life for myasthenia gravis","volume":"38","author":"Mullins","year":"2008","journal-title":"Muscle & Nerve"},{"issue":"8","key":"10.1002\/14651858.CD016208-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","article-title":"Fatigue in patients with myasthenia gravis. A systematic review of the literature","volume":"30","author":"Ruiter","year":"2020","journal-title":"Neuromuscular Disorders: NMD"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mus.26069","article-title":"Fatigue is a relevant outcome in patients with myasthenia gravis","volume":"58","author":"Tran","year":"2018","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD016208-BIB0062|cit62","unstructured":"Covidence Veritas Health Innovation 2024"},{"key":"10.1002\/14651858.CD016208-BIB0063|cit63","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD016208-BIB0064|cit64","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD016208-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016208-BIB0066|cit66","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016208-BIB0067|cit67","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016208-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Medical Research Methodology"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"4","key":"10.1002\/14651858.CD016208-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"27","key":"10.1002\/14651858.CD016208-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"10","key":"10.1002\/14651858.CD016208-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLOS ONE"},{"issue":"23","key":"10.1002\/14651858.CD016208-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/sim.4001","article-title":"Evaluating novel agent effects in multiple-treatments meta-regression","volume":"29","author":"Salanti","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD016208-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD016208-BIB0075|cit75","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1536867X1101100206","article-title":"Multivariate random-effects meta-regression: updates to mvmeta","volume":"11","author":"White","year":"2011","journal-title":"Stata Journal"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD016208-BIB0078|cit78","unstructured":"Stata StataCorp 2019"},{"key":"10.1002\/14651858.CD016208-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jclinepi.2016.02.016","article-title":"The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes","volume":"76","author":"Veroniki","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016208-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD016208-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Statistical Methods in Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"Journal of the Royal Statistical Society. Series A: Statistics in Society"},{"issue":"7804","key":"10.1002\/14651858.CD016208-BIB0083|cit83","first-page":"964","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD016208-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/1536867X1501500402","article-title":"Visualizing assumptions and results in network meta-analysis: the network graphs package","volume":"15","author":"Chaimani","year":"2015","journal-title":"Stata Journal"},{"key":"10.1002\/14651858.CD016208-BIB0086|cit86","unstructured":"Chaimani A Caldwell DM Li T Higgins JP Salanti G Chapter 11: Undertaking network meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0088|cit88","first-page":"159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Medicine 2013"},{"issue":"7","key":"10.1002\/14651858.CD016208-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLOS ONE"},{"issue":"7521","key":"10.1002\/14651858.CD016208-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"issue":"20","key":"10.1002\/14651858.CD016208-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1471-2288-12-138","article-title":"Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons","volume":"12","author":"Song","year":"2012","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1471-2288-14-106","article-title":"Characteristics of a loop of evidence that affect detection and estimation of inconsistency: a simulation study","volume":"14","author":"Veroniki","year":"2014","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD016208-BIB0095|cit95","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health","volume":"67","author":"O'Neill","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016208-BIB0097|cit97","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"3","key":"10.1002\/14651858.CD016208-BIB0098|cit98","first-page":"149","article-title":"Myasthenia gravis: diagnosis and treatment","volume":"16","author":"Stacy","year":"2010","journal-title":"Neurologist"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0099|cit99","first-page":"141","article-title":"Autoimmune disorders of neuromuscular transmission","volume":"26","author":"Vincent","year":"2002","journal-title":"Muscle & Nerve"},{"issue":"7651","key":"10.1002\/14651858.CD016208-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"GRADE: what is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1002\/14651858.CD016208-BIB0101|cit101","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD016208-BIB0102|cit102","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD016208-BIB0103|cit103","unstructured":"Institute of Social and Preventive Medicine, University of Bern CINeMA: Confidence in Network Meta-Analysis Institute of Social and Preventive Medicine, University of Bern 2017"},{"key":"10.1002\/14651858.CD016208-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.04.018","article-title":"Development of the summary of findings table for network meta-analysis","volume":"115","author":"Yepes-Nu\u00f1ez","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD016208-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1355819619841647","article-title":"Development of the ACTIVE framework to describe stakeholder involvement in systematic reviews","volume":"24","author":"Pollock","year":"2019","journal-title":"Journal of Health Services Research & Policy"},{"issue":"6","key":"10.1002\/14651858.CD016208-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002828.pub2","article-title":"Corticosteroids for myasthenia gravis","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1749-6632.2012.06804.x","article-title":"Phase II trial of methotrexate in myasthenia gravis","volume":"1275","author":"Pasnoor","year":"2012","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD016208-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0192-0561(95)00009-Q","article-title":"Leflunomide prevents the development of experimentally induced myasthenia gravis","volume":"17","author":"Vidic-Dankovic","year":"1995","journal-title":"International Journal of Immunopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD016208-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD016208-BIB0111|cit111","first-page":"1180","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD016208-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1002\/14651858.CD016208-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","article-title":"Cyclosporine in the treatment of myasthenia gravis","volume":"111","author":"Lavrnic","year":"2005","journal-title":"Acta Neurologica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD016208-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40265-018-0889-3","article-title":"Eculizumab: a review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"issue":"12","key":"10.1002\/14651858.CD016208-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Utsugisawa","year":"2017","journal-title":"Lancet. Neurology."},{"issue":"1","key":"10.1002\/14651858.CD016208-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle & Nerve"},{"issue":"7","key":"10.1002\/14651858.CD016208-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses","volume":"8","author":"Karam","year":"2021","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"8","key":"10.1002\/14651858.CD016208-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD016208-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"issue":"5","key":"10.1002\/14651858.CD016208-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Bresch","year":"2023","journal-title":"Lancet. Neurology"},{"issue":"4","key":"10.1002\/14651858.CD016208-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:24:10Z","timestamp":1749032650000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016208"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":121,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016208","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}